NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis $3.06 +0.05 (+1.50%) As of 10:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pyxis Oncology Stock (NASDAQ:PYXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pyxis Oncology alerts:Sign Up Key Stats Today's Range$3.00▼$3.1950-Day Range$1.63▼$3.0152-Week Range$0.97▼$5.55Volume135,359 shsAverage Volume717,798 shsMarket Capitalization$193.53 millionP/E RatioN/ADividend YieldN/APrice Target$6.83Consensus RatingModerate Buy Company Overview Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies. Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens. The company’s proprietary conjugation technology is intended to optimize drug‐to‐antibody ratios and stability in circulation, enabling more efficient tumor penetration and payload release. While most programs are currently in preclinical or Phase I development, Pyxis’s strategic approach seeks to address cancers that have historically proven resistant to standard treatments, including triple‐negative breast cancer and certain gastrointestinal malignancies. Headquartered in Boston, Massachusetts, Pyxis Oncology conducts research and clinical activities across the United States, with plans to expand trials into Europe and Asia as programs advance. The organization draws on expertise from seasoned professionals in oncology drug discovery, translational research and clinical development. Pyxis Oncology continues to collaborate with academic institutions and contract research organizations to accelerate its mission of bringing safer, more effective cancer therapies to patients worldwide.AI Generated. May Contain Errors. Read More Pyxis Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScorePYXS MarketRank™: Pyxis Oncology scored higher than 54% of companies evaluated by MarketBeat, and ranked 465th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingPyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPyxis Oncology has a consensus price target of $6.83, representing about 122.4% upside from its current price of $3.07.Amount of Analyst CoveragePyxis Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Pyxis Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pyxis Oncology are expected to grow in the coming year, from ($1.23) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pyxis Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.37% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 4.85.Change versus previous monthShort interest in Pyxis Oncology has recently increased by 15.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.77 News SentimentPyxis Oncology has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.Search Interest4 people have searched for PYXS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of Pyxis Oncology is held by insiders.Percentage Held by Institutions39.07% of the stock of Pyxis Oncology is held by institutions.Read more about Pyxis Oncology's insider trading history. Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PYXS Stock News HeadlinesPyxis Oncology Secures $50 Million Private Placement to Extend Cash Runway and Fund MICVO Clinical DevelopmentJune 30 at 7:51 AM | quiverquant.comQPyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical MilestonesJune 30 at 7:30 AM | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 1 at 1:00 AM | Banyan Hill Publishing (Ad)Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 26, 2026 | americanbankingnews.comPyxis Oncology Announces Interim CEO Amid Leadership TransitionJune 24, 2026 | theglobeandmail.comPyxis Oncology Stockholders Approve Directors and Auditor SlateJune 15, 2026 | tipranks.comAnalysts See Nearly 3X Upside in Pyxis Oncology (PYXS)June 10, 2026 | insidermonkey.comAnalysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)May 19, 2026 | theglobeandmail.comSee More Headlines PYXS Stock Analysis - Frequently Asked Questions How have PYXS shares performed this year? Pyxis Oncology's stock was trading at $1.15 at the beginning of the year. Since then, PYXS stock has increased by 167.2% and is now trading at $3.0730. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.02. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an IPO on Wednesday, October 6th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pyxis Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Home Depot (HD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/14/2026Today7/01/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PYXS's financial health is in the Green zone, according to TradeSmith. PYXS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PYXS CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees60Year Founded2019Price Target and Rating Average Price Target for Pyxis Oncology$6.83 High Price Target$8.00 Low Price Target$5.00 Potential Upside/Downside+124.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.62 million Net MarginsN/A Pretax Margin-579.80% Return on Equity-135.60% Return on Assets-85.00% Debt Debt-to-Equity RatioN/A Current Ratio2.76 Quick Ratio2.76 Sales & Book Value Annual Sales$13.86 million Price / Sales13.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book3.55Miscellaneous Outstanding Shares63,350,000Free Float59,744,000Market Cap$193.28 million OptionableOptionable Beta1.42 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PYXS) was last updated on 7/1/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
